Patent application number | Description | Published |
20100240545 | BIOMARKERS FOR INFLAMMATION OF THE LIVER - The invention relates to a method for the diagnostic investigation of biological samples from a person for inflammation of the liver, in particular hepatic fibrosis and/or cirrhosis of the liver, where the sample is investigated for one or more proteins as markers of inflammation of the liver, in particular hepatic fibrosis and/or cirrhosis of the liver, where a concentration of the proteins which is elevated or decreased by comparison with the healthy state indicates the presence of an inflammation of the liver, in particular a hepatic fibrosis and/or cirrhosis of the liver. The proteins are selected from the group of ER6Q, vimentin, actin alpha 1 skeletal muscle protein, hMFAP 4, tropomyosin, PTGES 2, amyloid P component, transgelin, calponin 1, homo sapiens p20 protein, 17 kDa M myosin light chain, H chain H Igg B12, prolyl 4-hydroxylase, beta subunit methylenetetrahydrofolate dehydrogenase 1, PRO2619, aldehyde dehydrogenase 1, fibrinogen alpha chain preproprotein, fructose-bisphosphate aldolase B, argininosuccinate synthetase, Eefla2, AT P 5 A1, alpha-2 actin, regucalcin, serum albumin, mitochondrial malate dehydrogenase, mitochondrial acetoacetyl-CoA thiolase or in each case a partial sequence thereof. | 09-23-2010 |
20110294136 | BIOMARKER FOR DIAGNOSING PANCREATIC CANCER - The invention relates to a method for diagnosing pancreatic cancer (PaCa) or the precursor diseases and/or concomitant diseases thereof, in particular pancreatic ductal adenocarcinoma (PDAC), pancreatic intraepithelial neoplasia (PanIN), pancreatic lesions, chronic pancreatitis (CP), including endocrine pancreatic tumors. In said method, the diagnosis is performed using selected biomarkers. The invention further relates to biomarker combinations suitable for carrying out said method, particularly for in vitro diagnosis. | 12-01-2011 |
20140045718 | BIOMARKERS FOR INFLAMMATION OF THE LIVER - The invention relates to a method for the diagnostic investigation of biological samples from a person for inflammation of the liver, in particular hepatic fibrosis and/or cirrhosis of the liver, where the sample is investigated for one or more proteins as markers of inflammation of the liver, in particular hepatic fibrosis and/or cirrhosis of the liver, where a concentration of the proteins which is elevated or decreased by comparison with the healthy state indicates the presence of an inflammation of the liver, in particular a hepatic fibrosis and/or cirrhosis of the liver.; The proteins are selected from the group of ER6Q, vimentin, actin alpha 1 skeletal muscle protein, hMFAP 4, tropomyosin, PTGES 2, amyloid P component, transgelin, calponin 1, homo sapiens p20 protein, 17 kDa myosin light chain, H chain H Igg B12, prolyl 4-hydroxylase, beta subunit methylenetetrahydrofolate dehydrogenase 1, PRO2619, aldehyde dehydrogenase 1, fibrinogen alpha chain preproprotein, fructose-bisphosphate aldolase B, argininosuccinate synthetase, Eefla2, AT P 5 Al, alpha-2 actin, regucalcin, serum albumin, mitochondrial malate dehydrogenase, mitochondrial acetoacetyl-CoA thiolase or in each case a partial sequence thereof. | 02-13-2014 |
Patent application number | Description | Published |
20120116082 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN SALTS - The present invention relates to a new process for the preparation of rosuvastatin [7-[4-(4-Fluorophenyl)-6-isopropyl-2-(methanesulphonyl-methyl-amino)-pyrimidin-5-yl]-(3R,51S)-dihydroxy-hept-6-enoic acid] of the formula (I) salts formed with bivalent cations, preferably with calcium or zinc ions, characterized in that rosuvastatin tert.-butylammonium salt is reacted with the appropriate bivalent cation, preferably with calcium or zinc ions in a mixture of a water immiscible or slightly miscible organic solvent and water and the formed salt is isolated. | 05-10-2012 |
20130296353 | CRYSTALLINE PHARMACEUTICALLY ACTIVE INGREDIENTS - The present invention is related to crystalline forms of rosuvastatin zinc (2:1) salt. The polymorphs are suitable for use as pharmaceutically active ingredients in the treatment of the diseases of the lipid metabolism including hypercholesterolemia, hyperlipidemia, dyslipidemia or atherosclerosis. | 11-07-2013 |
20130338360 | METHOD FOR THE PREPARATION OF HIGH-PURITY PHARMACEUTICAL INTERMEDIATES - The present invention is related to intermediates useful in the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S)-dihydroxy-hept-6-enoic acid and polymorphs of said intermediates, methods for preparation thereof and use thereof. | 12-19-2013 |
20140142303 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS - The invention relates to a process for the preparation of 5-chloro-N-({(5-S)-2-oxo3-[4-(3-oxo-morj)holine-4-yl)-phenyl]-1,3-oxazolidine-5-yl}-methyl) thiophen-2-carboxamide having the INN rivaroxaban. The process is characterized by the reactions according to claim | 05-22-2014 |
Patent application number | Description | Published |
20110282020 | PROCESS FOR PREPARING A POLYMER HAVING A 2,5-FURANDICARBOXYLATE MOIETY WITHIN THE POLYMER BACKBONE AND SUCH (CO)POLYMERS - A process for preparing a polymer having a 2,5-furandicarboxylate moiety within the polymer backbone and having a number average molecular weight of at least 10,000 (as determined by GPC based on polystyrene standards) includes a first step where a prepolymer is made having the 2,5-furandicarboxylate moiety within the polymer backbone, followed in a second step by a polycondensation reaction. In the first step a 2,5-furandicarboxylate ester is transesterified with a compound or mixture of compounds containing two or more hydroxyl groups, in the presence of a tin(IV) based transesterification catalyst. In the second step at reduced pressure and under melt conditions the prepolymer prepared in the first step is polycondensed in the presence of a tin (II) based polycondensation catalyst until the polymer is obtained. This polymer may then be subjected to Solid State Polycondensation. Polymers so produced may have a 2,5-furandicarboxylate moiety within the polymer backbone, and having a number average molecular weight of at least 20,000 (as determined by GPC based on styrene standards), and an absorbance as a 5 mg/mL solution in a dichloromethane:hexafluoroisopropanol 8:2 at 400 nm of below 0.05. | 11-17-2011 |
20130345453 | PROCESS FOR THE DEPOLYMERIZATION OF A FURANDICARBOXYLATE CONTAINING POLYESTER - A product including a furandicarboxylate compound and diol is obtained from a furandicarboxylate containing polyester in a process, which includes reacting a polymer composition including furandicarboxylate containing polyester with water or an alcohol, such as an alkyl alcohol with from 1 to 12 carbon atoms, in the presence of a base, that is preferably selected from the group consisting of metal hydrides, metal alkoxides, metal carbonates, metal carboxylates, N-heterocyclic carbenes, amidines, guanidines, phosphazenes and mixtures thereof. | 12-26-2013 |
20140336349 | A PROCESS FOR PREPARING A POLYMER PRODUCT HAVING A 2,5-FURANDICARBOXYLATE MOIETY WITHIN THE POLYMER BACKBONE TO BE USED IN BOTTLE, FILM OR FIBRE APPLICATIONS - A process for preparing a polymer having a 2,5-furandicarboxylate moiety within the polymer backbone, and having a number average molecular weight of at least 25,000, includes a transesterification step, a polycondensation step, a drying and/or crystallizing step, and a step where the polymer is subjected to post condensation conditions, and to a polyester-containing bottle or film or fibre-containing woven or non-woven object made from melt-processing poly(ethylene-2,5-furandicarboxylate), where the poly(ethylene-2,5-furandicarboxylate) is obtainable by the process of the invention. | 11-13-2014 |